Last reviewed · How we verify
rVSVΔG-ZEBOV
At a glance
| Generic name | rVSVΔG-ZEBOV |
|---|---|
| Also known as | BPSC-1001 |
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola (PHASE2)
- Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses (PHASE4)
- Partnership for Research on Ebola VACcinations (PHASE2)
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
- Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine (PHASE3)
- STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) (PHASE2, PHASE3)
- Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rVSVΔG-ZEBOV CI brief — competitive landscape report
- rVSVΔG-ZEBOV updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI